Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRB2 known ✓ | P07550 | 5/20 | 0.65 |
| ▸ | ADRB1 known ✓ | P08588 | 5/20 | 0.65 |
| ▸ | SIGMAR1 known ✓ | Q99720 | 4/20 | 0.65 |
| ▸ | ADRB3 known ✓ | P13945 | 4/20 | 0.65 |
| ▸ | HTR2A known ✓ | P28223 | 3/20 | 0.65 |
| ▸ | HTR2C known ✓ | P28335 | 3/20 | 0.65 |
| ▸ | HTR6 known ✓ | P50406 | 3/20 | 0.65 |
| ▸ | HTR1A known ✓ | P08908 | 2/20 | 0.65 |
| ▸ | SLC6A4 known ✓ | P31645 | 3/20 | 0.63 |
| ▸ | HTR2B known ✓ | P41595 | 3/20 | 0.63 |
| ▸ | HTR1B known ✓ | P28222 | 3/20 | 0.63 |
| ▸ | SCN1A known ✓ | P35498 | 2/20 | 0.63 |
| ▸ | SCN2A known ✓ | Q99250 | 2/20 | 0.63 |
| ▸ | SCN3A known ✓ | Q9NY46 | 2/20 | 0.63 |
| ▸ | ADRA2A known ✓ | P08913 | 1/20 | 0.63 |
| ▸ | ADRA2C known ✓ | P18825 | 1/20 | 0.63 |
| ▸ | SLC6A2 known ✓ | P23975 | 1/20 | 0.63 |
| ▸ | AGTR1 known ✓ | P30556 | 1/20 | 0.63 |
| ▸ | ADRA1A known ✓ | P35348 | 1/20 | 0.63 |
| ▸ | OPRM1 known ✓ | P35372 | 1/20 | 0.63 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL896467 | 0.99 | NR2E1 (0.74) | NR2E1ADRB2ADRB1SIGMAR1ADRB3 | |
| SCHEMBL19440598 | 0.84 | NR2E1 (1.00) | NR2E1ADRB2ADRB1SIGMAR1ADRB3 | |
| SCHEMBL10737803 | 0.83 | NR2E1 (0.78) | NR2E1ADRB2ADRB1SIGMAR1ADRB3 | |
| SCHEMBL1298843 | 0.83 | NR2E1 (0.78) | NR2E1ADRB2ADRB1SIGMAR1ADRB3 | |
| SCHEMBL11742816 | 0.83 | NR2E1 (0.78) | NR2E1ADRB2ADRB1SIGMAR1ADRB3 | |
| SCHEMBL14070176 | 0.82 | NR2E1 (0.76) | NR2E1ADRB2ADRB1SIGMAR1ADRB3 | |
| SCHEMBL11226386 | 0.81 | NR2E1 (0.71) | NR2E1ADRB2ADRB1SIGMAR1ADRB3 | |
| SCHEMBL6018298 | 0.81 | NR2E1 (0.74) | NR2E1ADRB2ADRB1SIGMAR1ADRB3 | |
| SCHEMBL19031799 | 0.81 | NR2E1 (0.74) | NR2E1ADRB2ADRB1SIGMAR1ADRB3 | |
| SCHEMBL22354430 | 0.80 | NR2E1 (0.74) | NR2E1ADRB2ADRB1SIGMAR1ADRB3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140343160-A1 | ADHESIVE MIXTURE FOR TRANSDERMAL DELIVERY OF HIGHLY PLASTICIZING DRUGS | BERTEK, INC. | 2014-11-20 | — | — | US | disclosed |
| US-8846093-B2 | Adhesive mixture for transdermal delivery of highly plasticizing drugs | MYLAN TECHNOLOGIES, INC. (US) | 2014-09-30 | — | — | US | disclosed |
| US-20140243379-A1 | ADHESIVE MIXTURE FOR TRANSDERMAL DELIVERY OF HIGHLY PLASTICIZING DRUGS | MYLAN TECHNOLOGIES, INC. (US) | 2014-08-28 | — | — | US | disclosed |
| US-20130018078-A1 | ADHESIVE MIXTURE FOR TRANSDERMAL DELIVERY OF HIGHLY PLASTICIZING DRUGS | MYLAN TECHNOLOGIES INC. (US) | 2013-01-17 | — | — | US | disclosed |
| US-20120083535-A1 | ADHESIVE MIXTURE FOR TRANSDERMAL DELIVERY OF HIGHLY PLASTICIZING DRUGS | BERTEK, INC. | 2012-04-05 | — | — | US | disclosed |
| US-20100040690-A1 | Adhesive mixture for transdermal delivery of highly plasticizing drugs | MYLAN TECHNOLOGIES, INC. | 2010-02-18 | — | — | US | disclosed |
| US-7638140-B2 | Adhesive mixture for transdermal delivery of highly plasticizing drugs | MYLAN TECHNOLOGIES, INC. (US) | 2009-12-29 | — | — | US | disclosed |
| US-20090041832-A1 | Adhesive mixture for transdermal delivery of highly plasticizing drugs | MYLAN TECHNOLOGIES, INC. | 2009-02-12 | — | — | US | disclosed |
| US-7150881-B2 | Adhesive mixture for transdermal delivery of highly plasticizing drugs | MYLAN TECHNOLOGIES, INC. (US) | 2006-12-19 | — | — | US | disclosed |
| US-7070808-B2 | Adhesive mixture for transdermal delivery of highly plasticizing drugs | MYLAN TECHNOLOGIES, INC. (US) | 2006-07-04 | — | — | US | disclosed |
| EP-1561461-A2 | Adhesive mixture for transdermal delivery of highly plasticizing drugs | MYLAN TECHNOLOGIES, INC. (US) | 2005-08-10 | — | — | EP | disclosed |
| US-20040137046-A1 | such as selegiline and/or the use of protonated forms of various drugs; an adhesive, the drug in protonated form, a nonaqueous solvent that dissolves said drug in either protonated or unprotonated form, and a biocompatible deprotonating agent | MYLAN TECHNOLOGIES, INC. | 2004-07-15 | — | — | US | disclosed |
| US-20020150613-A1 | Patches; sustained release drug delivery | MYLAN TECHNOLOGIES, INC. | 2002-10-17 | — | — | US | disclosed |
| US-20010006628-A1 | Comprising an adhesive, drug in protonated form, a nonaqueous solvent capable of dissolving nonprotonated and protonated forms of the drug, and a biocompatible deprotonating agent to deprotonate the drug without irritating the skin | MYLAN TECHNOLOGIES, INC. | 2001-07-05 | — | — | US | disclosed |
| EP-0887075-A2 | Adhesive mixture for transdermal delivery of highly plasticizing drugs | BERTEK, INC. (US) | 1998-12-30 | — | — | EP | disclosed |